Annual Report 2018/19
To our shareholders
Letter to shareholders
Sonova continued to deliver on its strategy in 2018/19. Highlights included the launch of a leading-edge new technology platform, delivering the highest level of hearing performance; an emphasis on operational excellence in audiological care; and good progress in cochlear implants.
Group sales were CHF 2,763.2 million, an increase of 4.4% in Swiss francs and of 4.1% in local currencies. Organic growth stood at 4.9% in local currencies.
The adjusted Group EBITA reached CHF 594.0 million, up 7.7% in Swiss francs and 6.7% in local currencies. As reported, Group EBITA reached CHF 582.5 million, up 9.4% over the prior year in Swiss Francs.